Concurrent use or anticipated need for medications that are mainly metabolized by UGTA including their administration within -days prior to the first dose of study drug (e.g., raloxifene, valproic acid, propofol, propranolol, dapagliflozin, darexaban, mycophenolic acid, and tapentadol)
Concomitant therapy with valproic acid/valproate-containing therapies
Patients who are being treated with Valproic Acid for any of its indication (epilepsy, mood disorder) must be excluded or must stop using the medication.
Patients requiring concurrent administration of valproic acid are not eligible for this trial
Patients who will need valproic acid for any medical condition during the study or within  days prior to first panobinostat treatment
Needing valproic acid for any medical condition during the study or within  days prior to first panobinostat treatment
History of severe allergic reaction to sunitinib or valproic acid; inability to receive sunitinib or valproic acid
Previous treatment with sunitinib or valproic acid for uveal melanoma
Active treatment with valproic acid for non-oncological conditions, if this cannot be safely switched to an alternative agent
Prior myelosuppressive chemotherapy or other investigational drug therapy within the last  months prior to initiation of sunitinib or valproic acid
Any condition that would prohibit patient from initiating valproic acid; current or prior valproic acid treatment is allowed (do not need to be >= lower limit of normal [LLN] for laboratory for enrollment)
History of valproic acid (VPA) use
Patients must not have received valproic acid within  days of study entry
Patients requiring concomitant therapy with phenytoin, phenobarbital, carbamazepine, or valproic acid
Patients who will need valproic acid for any medical condition during the study or within  days prior to first panobinostat treatment
Use of any UDP glucuronosyltransferase  family, polypeptide A (UGTA) inhibitor including: acitretin, amitriptyline, androsterone, cyclosporine, dasatinib, diclofenac, diflunisal, efavirenz, erlotinib, estradiol (-beta), flutamide, geftinib, gemfibrozil, glycyrrhetinic acid, glycyrrhizin, imatinib, imipramine, ketoconazole, lineoleic acid, mefenamic acid, mycophenolic acid, niflumic acid, nilotinib, phenobarbital, phenylbutazone, phenytoin, probenecid propofol, quinidine, ritonavir, Sorafenib, sulfinpyrazone, valproic acid and verapamil from screening through follow-up period
Patients asking or who have had prior treatment with a drug like vorinostat (i.e., valproic acid) within the last  days
Patient needing valproic acid during the study or within  days prior to first dose
Patients who will need valproic acid for any medical condition during the study or within  days prior to first PANOBINOSTAT treatment
Patients who will need valproic acid for any medical condition during the study or within  days prior to first panobinostat treatment
Patients who will need valproic acid for any medical condition during the study or within  days prior to first panobinostat treatment
Valproic acid for the treatment of cancer
Patients who will need valproic acid for any medical condition during the study or within  days prior to first panobinostat treatment
Patients who will need valproic acid for any medical condition during the study or within  days prior to first panobinostat treatment
Allergy to valproic acid
Concurrent use of valproic acid is not allowed
Patients receiving valproic acid (VPA), an anticonvulsant drug with HDAC inhibitor properties, will be excluded, unless they are switched to an alternative agent prior to treatment initiation. No wash out period is required.
Patients who will need valproic acid for any medical condition during the study or within  days prior to first panobinostat treatment
Patients will be excluded if they are receiving Valproic Acid (VPA) therapy.
Patients who will need valproic acid for any medical condition during the study or within  days prior to first LBH treatment
Patients will be excluded if they have received previous therapy with HDAC, DAC, HSP inhibitors or valproic acid anticancer therapy. Valproic acid therapy is not allowed for any reason while on this study.
Patients must not be receiving valproic acid
Patients who will need valproic acid for any medical condition during the study or within  days prior to first panobinostat treatment
Treatment with valproic acid within  days prior to initiation of study and during the study
Use of valproic acid for any medical condition while receiving protocol treatment or within  days prior to first panobinostat dose
Any drug that results in hepatic enzyme induction such as anti-convulsants (phenytoin, valproic acid, carbamazepine, phenobarbital); Keppra (levetiracetam) is allowed
Patients requiring concurrent administration of valproic acid are also excluded
Patients currently taking valproic acid
Patients who will need valproic acid for any medical condition during the study or within  days prior to first PANO treatment
Any contraindication to dexamethasone or valproic acid such as known allergies or sensitivity